Literature DB >> 17987877

Pay for performance for antibiotic timing in pneumonia: caveat emptor.

Jesse M Pines1, Judd E Hollander, Elizabeth M Datner, Joshua P Metlay.   

Abstract

BACKGROUND: Health care practitioners and hospital administrators have focused on a performance measure regarding antibiotic timing for patients with community-acquired pneumonia in anticipation of a pay-for-performance program through the Centers for Medicare & Medicaid Services (CMS) and private payers. ANTIBIOTIC TIMING AS A PERFORMANCE MEASURE: Early antibiotic administration is associated with improved outcomes, even after adjusting for severity. Yet although some patients may benefit through the early administration of antibiotics, there is a risk to other patients who are treated concurrently. Some patients' care may be delayed because they may not receive the same priority as patients with suspected pneumonia. Other patients may receive inappropriate antibiotics for suspected pneumonia to shorten the time to administration. POTENTIAL IMPACT OF PAY FOR PERFORMANCE: Attempts to address the performance measure are probably dependent on how well the emergency department functions and the level of crowding. Patients with a suspected pneumonia may be empirically covered with antibiotics before radiographic diagnosis, which should increase the rate of antibiotic administration for antibiotic-nonresponsive conditions and contribute to antibiotic resistance. The answer is to find measures of system throughput and/or work flow that are associated with improved patient care outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17987877     DOI: 10.1016/s1553-7250(06)32069-7

Source DB:  PubMed          Journal:  Jt Comm J Qual Patient Saf        ISSN: 1553-7250


  3 in total

1.  The regulation of infection.

Authors:  L E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-03       Impact factor: 2.471

2.  Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia.

Authors:  A H W Bruns; J J Oosterheert; W N M Hustinx; C A J M Gaillard; E Hak; A I M Hoepelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-03-12       Impact factor: 3.267

3.  Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.

Authors:  Daniel M Musher; Ingrid L Roig; Guillermo Cazares; Charles E Stager; Nancy Logan; Hossam Safar
Journal:  J Infect       Date:  2013-03-19       Impact factor: 6.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.